NeuroMetrix Reports Q1 2024 Business Highlights

Core Insights - NeuroMetrix, Inc. reported a decline in revenue for Q1 2024, primarily due to reduced sales volume for DPNCheck, with total revenue of $1.1 million, a decrease of 37% from Q1 2023 [4][9] - The company is focusing on maximizing shareholder value and has made strategic decisions to expand its Board of Directors and reduce operating expenses by downsizing its workforce [2] Business Highlights - Quell® Fibromyalgia has shown sequential revenue growth since its launch in late 2022, with significant sales coming from the commercial healthcare provider channel [2] - The DPNCheck® business is experiencing revenue erosion due to changes in the Medicare Advantage market, impacting patient screening compensation [2] - The company is exploring value-based care opportunities outside the Medicare Advantage market to mitigate challenges [2] Financial Results - Q1 2024 revenue was $1.1 million, down from $1.7 million in Q1 2023, with a gross margin rate of 47%, down from 69% in the previous year [4][9] - Operating expenses increased to $3.8 million in Q1 2024, up by $0.9 million from Q1 2023, driven by costs related to workforce reduction and professional services [4][9] - The net loss for Q1 2024 was $3.0 million ($1.67 per share), compared to a net loss of $1.6 million ($1.64 per share) in Q1 2023 [4][9] Operational Metrics - In Q1 2024, unique prescribers for Quell® increased by 11% to 221, with a total of 895 prescriptions written, reflecting a 54% increase [7] - A total of 454 devices were shipped, marking a 28% increase, and electrode refills rose to 666 months, a 26% increase [7] - Over 2,000 patients with fibromyalgia have been prescribed Quell since its launch in December 2022 [7] Research and Development - A recent study validated the effectiveness of DPNCheck in detecting diabetic peripheral neuropathy, contributing to the clinical validation of the technology [7]